However the company does have a SGLT2 drug, Farxiga, which could have a similar CV profile to Jardiance. In March, AstraZeneca announced an analysis of real world data from more than 300,000 ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly-priced new contender. The FDA approved Steglatro (ertugliflozin) as a monotherapy in conjunction with diet and ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found ...

Top Medicare Part D drugs without price negotiations have seen a 98% increase in list prices since their launch. Read more ...

More than two years after the passage of the Inflation Reduction Act (“IRA”) and the Centers for Medicare and Medicaid Services’ (“CMS’”) ...

A study comparing oral glucose-lowering agents to insulin for gestational diabetes found no non-inferiority in preventing ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

If you’re looking for an OTC medication that’ll ease pain and quell inflammation, there are several great options to choose ...

Approximately half of all respondents reported that their facility uses tall man lettering for similar drug names that appear on pharmacy computer drug selection screens, computer-generated ...